DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care
The system is powered by advanced imaging innovations such as Amber-red Color Imaging, Triple Noise Reduction, and Extended Dynamic Range Image Processing
Over 1500 stakeholders representing food businesses, packaging industries, recycling associations, regulatory bodies, environmental organizations, consumer groups, farmer groups, government departments participated in the consultation
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Zydus MedTech gets rights to market the innovative Transcatheter Aortic Valve Implantation (TAVI) technology in India, Europe and other select markets
The merged entity ‘Aster DM Quality Care’ will be jointly controlled by Aster Promoters and Blackstone
According to IQVIATM sales data for the 12-month period ending February 2025, the Adderall Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market3 achieved annual sales of approximately $421.7 million.
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
Genomics is transforming the future of modern medicine and treatment modalities across specialties
The plant will have installed production capacity of 3,120 MT/month
Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities
The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
The approved product, Mesalamine Suppositories 1000 mg, has an estimated U.S. market size of US$ 29 million
Fluralaner invented by Nissan Chemical is the active pharmaceutical ingredient of BRAVECTO and EXZOLT,
This change is subject to the approval of the shareholders of the company, the Ministry of Corporate Affairs and other statutory and regulatory authorities,
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Subscribe To Our Newsletter & Stay Updated
